- Home
- PHAR vs NTGR Comparison
PHAR vs NTGR Comparison
Compare PHAR & NTGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NTGR
- Stock Information
- Founded
- PHAR 1988
- NTGR 1996
- Country
- PHAR Netherlands
- NTGR United States
- Employees
- PHAR N/A
- NTGR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NTGR Telecommunications Equipment
- Sector
- PHAR Health Care
- NTGR Utilities
- Exchange
- PHAR Nasdaq
- NTGR Nasdaq
- Market Cap
- PHAR 951.7M
- NTGR 941.6M
- IPO Year
- PHAR N/A
- NTGR N/A
- Fundamental
- Price
- PHAR $13.18
- NTGR $29.30
- Analyst Decision
- PHAR Strong Buy
- NTGR Strong Buy
- Analyst Count
- PHAR 3
- NTGR 3
- Target Price
- PHAR $30.00
- NTGR $39.00
- AVG Volume (30 Days)
- PHAR 9.7K
- NTGR 645.3K
- Earning Date
- PHAR 11-06-2025
- NTGR 10-29-2025
- Dividend Yield
- PHAR N/A
- NTGR N/A
- EPS Growth
- PHAR N/A
- NTGR N/A
- EPS
- PHAR N/A
- NTGR N/A
- Revenue
- PHAR $339,836,000.00
- NTGR $699,572,000.00
- Revenue This Year
- PHAR $17.70
- NTGR $4.49
- Revenue Next Year
- PHAR $12.25
- NTGR $3.83
- P/E Ratio
- PHAR N/A
- NTGR N/A
- Revenue Growth
- PHAR 22.44
- NTGR 2.88
- 52 Week Low
- PHAR $7.31
- NTGR $18.75
- 52 Week High
- PHAR $17.08
- NTGR $36.86
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- NTGR 37.66
- Support Level
- PHAR $13.03
- NTGR $28.80
- Resistance Level
- PHAR $13.43
- NTGR $35.10
- Average True Range (ATR)
- PHAR 0.49
- NTGR 1.59
- MACD
- PHAR -0.10
- NTGR -0.58
- Stochastic Oscillator
- PHAR 23.47
- NTGR 7.94
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NTGR NETGEAR Inc.
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: NETGEAR for Business and Connected Home which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Connected Home segment offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.